Skip to main content

Advertisement

Table 2 Baseline characteristics of patients at index or during 12 months before index prescription

From: Factors associated with physicians’ prescriptions for rheumatoid arthritis drugs not filled by patients

  Methotrexate (MTX) Biologics/tofacitinib (B/T)
Noninitiators (n = 281) Initiators (n = 482) Total (n = 763) Noninitiators (n = 176) Initiators (n = 258) Total (n = 434)
Age at index prescription, mean (SD) 67.6 (12.7) 59.5 (13.5) 62.5 (13.8) 63.0 (13.7) 54.0 (13.4) 57.7 (14.2)
Female (%) 73.3 71.6 72.2 74.4 77.1 76.4
Race (%)
 White 87.5 78.4 81.8 83.0 80.2 81.3
 African American 5.7 8.1 7.2 5.1 7.4 6.5
 Asian 2.1 2.1 2.1 0.6 1.2 0.9
 Other/unknown 4.6 11.4 8.9 11.4 11.2 11.3
Geographic division (%)a
 East North Central 14.2 23.2 19.9    
 East South Central 1.8 0.8 1.2    
 Middle Atlantic 5.7 10.0 8.4    
 Mountain 2.1 2.9 2.6    
 New England 16.7 3.1 8.1    
 Other/unknown 1.8 2.5 2.2    
 Pacific 8.2 8.9 8.7    
 South Atlantic/West South Central 24.2 36.9 32.2    
 West North Central 25.3 11.6 16.6    
Commercial insurance (vs Medicare) at index (%)a,b 29.9 58.5 47.7 34.1 79.5 61.5
Body mass index during 12 months before index (from EHRs) (%)a
 Underweight (< 18.5) 1.4 2.1 1.8    
 Healthy weight (18.5–24.9) 16.4 21.4 19.5    
 Overweight (25.0–29.9) 20.6 23.9 22.7    
 Obesity I (30.0–34.9) 11.7 18.5 16.0    
 Obesity II (35.0–39.9) 6.4 8.5 7.7    
 Obesity III (40.0+) 5.3 7.9 6.9    
 Missing 38.1 17.8 25.3    
Active ingredient counts during 12 months before index (from claims)a, mean (SD) 3.4 (6.4) 10.5 (6.8) 7.9 (7.5)    
Number of days between RA diagnosis (from claims) and first prescription (from EHRs)a, median; mean (SD) 371 39 90    
602 279 398    
(698) (502) (602)    
Diagnosis-based comorbidity indicators (EDCs) during 12 months before index (based on claims) (%)
 ADM05: administrative concerns and nonspecific laboratory abnormalitiesa 70.5 60.0 63.8    
 GUR11: incontinencea 6.0 1.2 3.0    
Pharmacy-based comorbidity indicators (RxMGs) during 12 months before index (based on claims) (%)
 MUSx020: musculoskeletal/inflammatory conditionsb     71.6 91.5 83.4
 ALLx030: allergy/immunology/chronic inflammatorya,b 14.2 66.6 47.3 47.2 76.0 64.3
 CARx030: cardiovascular/high blood pressurea 13.5 45.4 33.7    
 GSIx020: general signs and symptoms/paina 17.8 59.1 43.9    
 GSIx030: general signs and symptoms/pain and inflammationa 12.5 56.4 40.2    
 INFx020: infections/acute minora 18.1 61.2 45.3    
 ENDx040: endocrine/diabetes without insulina 0.7 11.0 7.2    
  1. SD standard deviation, EHR electronic health record, RA rheumatoid arthritis, EDC Expanded Diagnosis Cluster, RxMG Rx-defined Morbidity Group
  2. aImportant predictors selected by LASSO logistic regression for predicting MTX primary nonadherence
  3. bImportant predictors selected for predicting B/T primary nonadherence; age, sex, and race were added to the predictive models regardless